¿Cómo curará la ceguera corneal la terapia celular? La terapia celular del endotelio corneal emerge como alternativa al trasplante, con datos clínicos y aprobaciones en Japón y Estados Unidos. La alternativa al trasplante empieza a dejar de ser promesa...

¿Cómo curará la ceguera corneal la terapia celular? #TerapiaCelular #Córnea #EndotelioCorneal #Oftalmología #Salud #InnovaciónMédica #Vyznova #AURN001 #DMEK #RMAT #10denoviembre #felizlunes #España #PMDA #FDA

donporque.com/terapia-celu...

Hematology Weekly News – August 18th 2025 🔬🧬 Hematology Updates: Kamada FDA Approval, ITP Trial Success, AI in Hemophilia and More From the FDA greenlighting one of […] The post Hematology Weekly News – August 18th 2025 appeared first on LucidQuest Ventures.

FYI: LucidQuest Views >>> Hematology Weekly News – August 18th 2025 #News #BloodDisorders #anemia #RMAT #CARNK Comment below!

Hematology Weekly News – August 18th 2025 🔬🧬 Hematology Updates: Kamada FDA Approval, ITP Trial Success, AI in Hemophilia and More From the FDA greenlighting one of […] The post Hematology Weekly News – August 18th 2025 appeared first on LucidQuest Ventures.

ICYMI: LucidQuest Views >>> Hematology Weekly News – August 18th 2025 #News #BloodDisorders #anemia #RMAT #CARNK Comment below!

Hematology Weekly News – August 18th 2025 🔬🧬 Hematology Updates: Kamada FDA Approval, ITP Trial Success, AI in Hemophilia and More From the FDA greenlighting one of […] The post Hematology Weekly News – August 18th 2025 appeared first on LucidQuest Ventures.

LucidQuest Views >>> Hematology Weekly News – August 18th 2025 #News #BloodDisorders #anemia #RMAT #CARNK Comment below!

Beam Therapeutics stock surges after FDA grants RMAT designation Investing.com -- Beam Therapeutics Inc. (NASDAQ:BEAM) stock surged 12% after the company announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to BEAM-101, its investigational cell therapy for sickle cell disease. The RMAT designation, which follows the orphan drug designation received earlier this year, provides Beam with opportunities for enhanced FDA collaboration, potential accelerated approval pathways, and possible priority review of future biologics license applications. This regulatory milestone recognizes BEAM-101’s potential as a one-time treatment for severe sickle cell disease. "We are thrilled that the FDA has granted RMAT designation to BEAM-101, following orphan drug designation earlier this year, reinforcing its potential as a one-time, best-in-class therapy for severe sickle cell disease," said Giuseppe Ciaramella, Ph.D., president of Beam Therapeutics. The company recently presented updated clinical data from its BEACON Phase 1/2 trial at the European Hematology Association Congress in June. Results from 17 treated patients showed robust increases in fetal hemoglobin, reductions in sickle hemoglobin, rapid cell engraftment, and improved markers of hemolysis and oxygen delivery. Notably, no vaso-occlusive crises were reported post-engraftment. Beam Therapeutics, which specializes in precision genetic medicines through base editing, has now dosed 30 patients in the BEACON trial and expects to present additional data later this year. The company’s manufacturing process for BEAM-101 utilizes an advanced, largely automated system that has consistently demonstrated high yields and viability. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. With BEAM making headlines, savvy investors are asking: Is it truly valued fairly? In a market full of overpriced darlings, identifying true value can be challenging. InvestingPro's advanced AI algorithms have analyzed BEAM alongside thousands of other stocks to uncover hidden gems. These undervalued stocks, potentially including BEAM, could offer substantial returns as the market corrects. In 2024 alone, our AI identified several undervalued stocks that later surged by 30 or more. Is BEAM poised for similar growth? Don't miss the opportunity to find out.

Click Subscribe #BeamTherapeutics #FDA #RMAT #SickleCellDisease #Investing

AbelZeta Receives FDA RMAT Designation for Groundbreaking C-CAR168 Therapy AbelZeta Pharma has achieved FDA's RMAT designation for C-CAR168, a promising therapy for treating refractory Systemic Lupus Erythematosus and Lupus Nephritis.

AbelZeta Receives FDA RMAT Designation for Groundbreaking C-CAR168 Therapy #United_States #Rockville #C-CAR168 #AbelZeta #RMAT

Many thanks to Rajesh Rao, MD and the clinical trial team at the University of Michigan Kellogg Eye Center, and to the wonderful dry AMD patients who have participated in the trial.

#MacularDegeneration #RMAT

@endpts.com

Stanford’s Pediatric Cancer Treatment Received FDA RMAT Designation - OncoDaily Stanford’s Pediatric Cancer Treatment Received FDA RMAT Designation / cancer, Crystal Mackall, diffuse intrinsic pontine glioma, FDA, Michelle Monje, Nature,

Stanford’s Pediatric Cancer Treatment Received FDA RMAT Designation
@stanfordmedicine.bsky.social
@michellemonje.bsky.social

oncodaily.com/insight/fda-...

#Cancer #DiffuseIntrinsicPontineGlioma #FDA #Nature #OncoDaily #Oncology #RegenerativeMedicine #Medicine #AdvancedTherapy #RMAT #Health